BrainGate™ is a transformative neurotechnology owned and operated by Tufts University that uses micro-electrodes implanted in the brain to let humans operate external devices such as computers or robotic arms with just their thought. Through years of advanced research, BrainGate™ is at the forefront of enabling severely motor-impaired individuals with the ability to communicate, interact, and function through thought. BrainGate™ is the only technology with an FDA-approved investigational device exemption to conduct human trials of brain-computer interface (BCI) technologies
Today, BrainGate™ is used to create technology that will allow severely disabled individuals—including those with traumatic spinal cord injury and loss of limbs—to communicate and control common every-day functions literally through thought. BrainGate, Inc.’s mission is to improve of the quality of life for all disabled humans as well as to increase the usage of BrainGate™ related technology in both medical and non-medical applications as a means to facilitate innovation in invasive and non-invasive brain research.
BrainGate, Inc. is focused on the advancement of the BrainGate™ Neural Interface System. BrainGate, Inc. owns the intellectual property of Cyberkinetics, as well as the intellectual property of the BrainGate™ system and any new technology further developed on the system by the company.
BrainGate, Inc. was founded by Jeffrey M. Stibel and a seasoned team of entrepreneurs with the hope to advance movement through thought alone. This was achieved alongside leading academic institutions, corporations, and various non-profit and government organizations working on the research, science, and development of applied commercial technology. In 2019, BrainGate™ and its core technology was donated to Tufts University as part of a larger grant to facilitate further research and practical applications.
Learn more about BrainGate™ research and development at Tufts: